Compare Quest Diagnostics Inc (DGX) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs F5 Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while F5 Inc trades at $479.83 (market cap $26.14B). The key difference: Quest Diagnostics Inc and F5 Inc are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and F5 Inc for 38 Days on average.
| DGX | FFIV | |
|---|---|---|
Market Cap | $25.48B | $26.14B |
Volume | 941,866 | 503,146 |
Sector | Health | Technology |
52-Week High | $247.45 | $479.83 |
52-Week Low | $173.49 | $223.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $31.23B | $24.78B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue and net income have shown steady growth, reaching $3.09 billion and $692.38 million in 2025, respectively. Positive sentiment is fueled by recent strategic partnerships and industry recognitions, such as being named a Leader in the IDC MarketScape for WAAP platforms.
The stock's valuation appears elevated with a P/E of 36.78 and P/S of 8.07, posing a risk if growth moderates. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite a majority Hold rating. Key investment opportunities include continued execution on AI security initiatives, while risks involve competitive pressures and reliance on enterprise spending. The stock's proximity to resistance at $468 warrants monitoring for breakout or pullback signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
